Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: May 25, 2011


Bruce Huebner has joined Vermillion's board of directors.

Huebner is a managing director at LynxCom Partners. He previously was president of Osmetech Molecular Diagnostics, president and chief operating officer of Nanogen, president and CEO of TrovaGene, and executive vice president and COO of Gen-Probe.

Huebner also held sales and marketing positions at Quidel, Hybritech, and Roche Diagnostics.

Stacey Sias has left Celera, where she served as senior vice president of business development and strategic planning and as an executive director. The company disclosed Sias's departure in a recent filing with the US Securities and Exchange Commission.

Sias previously was vice president of licensing at Roche Molecular Systems and a molecular biologist at Codon and Genentech. She is a registered patent agent with the US Patent and Trademark Office.

Cristopher McReynolds has been named vice president of business development at point-of-care testing developer Alverix. He previously was CEO of Satoris. Before that, McReynolds was VP of business development for Affymetrix's molecular diagnostics business unit, and prior to that held the same role at Cepheid.

Exosome Diagnostics, a developer of biofluid-based molecular diagnostic tests for use in personalized medicine, has appointed Bob Carter, Carlos Cordon-Cardo, Keith Flaherty, and John Quackenbush to its scientific advisory board.

Carter is professor and chief of neurosurgery at the University of California, San Diego, Medical Center where he co-leads the clinical brain tumor program.

Cordon-Cardo is vice chairman of pathology and professor of pathology and urology at Columbia University as well as associate director of infrastructure at the Herbert Irving Comprehensive Cancer Center.

Flaherty is director of developmental therapeutics at the Massachusetts General Hospital Cancer Center and a lecturer in the department of medicine at Harvard Medical School.

Quackenbush is professor of computational biology and bioinformatics at the Dana-Faber Cancer Institute.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.